Clinical trial
A Phase I Clinical Study of Novel Coronavirus Broad-spectrum Neutralizing Antibody SA55 Nasal Spray in Healthy People
NCT06048393 is registered in ClinicalTrials.gov with Sinovac Life Sciences Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Study of Novel Coronavirus Broad-spectrum Neutralizing Antibody SA55 Nasal Spray in Healthy People
- Lead sponsor
- Sinovac Life Sciences Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- May 31, 2023
- Completion date
- October 31, 2023
- Enrollment
- 80 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.